Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Prime Medicine, Inc. (PRME : NSDQ)

• Company Description    Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass. Number of Employees: 214

• Price / Volume Information    Yesterday's Closing Price: $3.47 Daily Weekly Monthly 20 Day Moving Average: 3,358,524 shares Shares Outstanding: 180.51 (millions) Market Capitalization: $626.37 (millions) Beta: 2.71 52 Week High: $6.94 52 Week Low: $1.11 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.87% -9.72% 12 Week -44.30% -45.20% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 First Street - Cambridge,MA 02141 USA ph: 617-564-0013 fax: - hannah.deresiewicz@sternir.com https://primemedicine.com

• General Corporate Information    Officers Keith Gottesdiener - President; Chief Executive Officer Allan Reine - Chief Financial Officer Carman Alenson - Chief Accounting Officer Thomas Cahill - Director Wendy Chung - Director Peer Information Prime Medicine, Inc. (CORR.) Prime Medicine, Inc. (RSPI) Prime Medicine, Inc. (CGXP) Prime Medicine, Inc. (BGEN) Prime Medicine, Inc. (GTBP) Prime Medicine, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74168J101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/27/26 Share - Related Items Shares Outstanding: 180.51 Most Recent Split Date: (:1) Beta: 2.71 Market Capitalization: $626.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.95 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.87 Price/Cash Flow: - Price / Sales: 104.80 EPS Growth vs. Year Ago Period: 27.27% vs. Previous Quarter: 21.95% Sales Growth vs. Year Ago Period: 486.12% vs. Previous Quarter: 9.87% ROE 12/31/25 - - 09/30/25 - -163.51 06/30/25 - -156.16 ROA 12/31/25 - - 09/30/25 - -61.21 06/30/25 - -64.41 Current Ratio 12/31/25 - - 09/30/25 - 6.61 06/30/25 - 3.56 Quick Ratio 12/31/25 - - 09/30/25 - 6.61 06/30/25 - 3.56 Operating Margin 12/31/25 - - 09/30/25 - -3,301.64 06/30/25 - -4,016.83 Net Margin 12/31/25 - - 09/30/25 - -3,301.64 06/30/25 - -4,016.83 Pre-Tax Margin 12/31/25 - - 09/30/25 - -3,301.64 06/30/25 - -4,016.83 Book Value 12/31/25 - - 09/30/25 - 0.90 06/30/25 - 0.45 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©